Log In
Print
BCIQ
Print
Print this Print this
 

DegludecPlus, Ryzodeg, insulin degludec/insulin aspart (IDegAsp) (NN5401)

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionCombination of 70% insulin degludec, a long-acting insulin analog, and 30% insulin aspart
Molecular Target Insulin receptor (INSR)
Mechanism of ActionInsulin receptor agonist
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentApproved
Standard IndicationDiabetes
Indication DetailsTreat diabetes; Treat Type I diabetes; Treat Type II diabetes
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today